Vitrase

DRUG6 trials

Sponsors

Bausch & Lomb Incorporated

Conditions

Diabetic RetinopathyDrug HypersensitivityPainVitreous DetachmentVitreous Hemorrhage

Phase 1

Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase)

CompletedNCT00198458

Bausch & Lomb IncorporatedDrug Hypersensitivity

Start: 2004-07-31End: 2004-09-30Target: 65Updated: 2013-03-18

Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase)

CompletedNCT00198419

Bausch & Lomb IncorporatedDrug Hypersensitivity

Start: 2004-03-31End: 2004-03-31Updated: 2013-03-14

Phase 2

Assessment of Intravitreous Injections of Vitrase for Inducing Posterior Vitreous Detachment

CompletedNCT00198471

Bausch & Lomb IncorporatedDiabetic Retinopathy, Vitreous Detachment

Start: 2005-07-31End: 2006-11-30Target: 10Updated: 2013-03-15

Phase 3

Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage

CompletedNCT00198510

Bausch & Lomb IncorporatedDiabetic Retinopathy, Vitreous Hemorrhage

Start: 1998-11-30End: 2003-03-31Target: 750Updated: 2013-03-15

Evaluation of Vitrase as a Spreading Agent

CompletedNCT00198484

Bausch & Lomb IncorporatedPain

Start: 2004-10-31End: 2005-02-28Updated: 2013-03-14

Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage

CompletedNCT00198497

Bausch & Lomb IncorporatedDiabetic Retinopathy, Vitreous Hemorrhage

Start: 1999-06-30End: 2003-06-30Target: 510Updated: 2013-03-15

Related Papers

Predicting response of vitreous hemorrhage after intravitreous injection of highly purified ovine hyaluronidase (Vitrase) in patients with diabetes.

2008-04-256 citations